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Abstract  
 
Naringenin, an abundant flavanon in the peel of citrus fruits is reported to possess anti-
proliferative effect in many cancer cells. Herein, we investigated the cytotoxic effect and 
apoptosis induction of naringenin in combination with doxorubicin on HeLa cells. The 
cytotoxicity assay of naringenin, doxorubicin, and their combination were carried out by using 
MTT assay. Cell viability was used as the parameters to evaluate combination effectiveness. 
Cell cycle distribution was determined by flow cytometry and analyzed using ModFit LT 3.0 
program. Apoptosic assay was done by double staining method using Ethidium Bromide-
Acridine Orange. Investigation on the expression of Bax and Bcl-2 were determined by 
immunocytochemistry method. Naringenin and doxorubicin showed cytotoxic effect on HeLa 
cells with their IC50 values of 195 µM and 1 µM, respectively. Whereas combination of 
naringenin-doxorubicin showed greater cytotoxicity compared the single treatment of 
doxorubicin. The strongest cytotoxic activity was observed at a combination of 100 µM 
naringenin and 0,5 µM doxorubicin. Single treatment of 0,5 µM doxorubicin for 24 hours on 
HeLa cells induced S-phase arrest while 100 µM naringenin did not affect on HeLa cell cycle. 
The combination induced S-phase arrest with the increased of sub-G1 phase percentage. In 
accordance with the flow cytometry results, the double staining apoptosis assay results showed 
the increase of apoptotic cells. Naringenin, doxorubicin, and their combination also increased 
the expression of Bax and decreased the expression of Bcl-2. These results concluded that 
naringenin was a potential co-chemotherapy agent for cervical cancer due to its synergism with 
doxorubicin. 
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INTRODUCTION 
 
Cervical cancer is one of the most common 
cancer in women. Many efforts have been made to 
cure the disease, such as using chemotherapy agent 
doxorubicin. Doxorubicin is a first line 
chemotherapy agent for cervical cancer. The 
mechanism of doxorubicin is believed through 
intercalating DNA and promoting the cleavage of 
DNA by inhibition of DNA topoisomerase II. It is 
also able to induce apoptosis by activating 
caspase-3 (Wang et al., 2004). Its therapeutic use 
is, however, is limited due to the severe 
cardiotoxicity and development of cell resistance 
(Gangadharan et al., 2009). To overcome such 
problems, strategies must be devised to improve its 
effectiveness. The best approach is through co-
chemotherapy, by combining doxorubicin with 
natural chemopreventive substances.  
One of them is naringenin, which had 
cytotoxic effect and caused cell death via apoptosis 
in various human cancer cells. The cytotoxic 
mechanism does not depend on p53, a tumor 
supressor gene (Kanno et al., 2005), so naringenin 
is promising cochemotherapy agent for cancer 
which has inactivated p53. 
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Enhancing cell cycle arrest and apoptosis 
induction of cancer cells is promising target to 
cure cancer. Therefore, the present study was 
carried out to address the objective wether 
naringenin could enhance the efficacy of 
chemotherapy agent, doxorubicin via cell 
cytotoxicity, cell cycle arrest, and apoptosis 
induction. 
 
MATERIALS AND METHODS 
 
Doxorubicin 
Doxorubicin (P.T. Ferron Par 
Pharmaceutical.) was diluted directly using culture 
medium DMEM right before treatment. The 
administered concentration series were 0,1-0,8 
µM. 
 
Naringenin 
Naringenin (NGEN) (Sigma Aldrich) was 
dissolved in dimethyl sulfoxide (DMSO) (Sigma) 
as stock solutions and diluted as desired directly in 
the culture medium. The administered 
concentration series were 25-1000 µM. 
 
Cell Culture 
HeLa cervical cancer cells was obtained 
from Cancer Chemoprevention Research Center 
(CCRC)-UGM. Cells were grown in DMEM 
(Dulbecco’s modified Eagle’s medium) (Gibco) 
supplemented with 10% fetal bovine serum 
(Gibco) and 1% Penicillin-Streptomycin (10.000 
unit/ml Penicillin and 10.000 µg/ml Streptomycin) 
(Gibco) and maintained in a humidified 
atmosphere containing 5% CO2 at 37˚C. The cell 
was cultured in 10 cm tissue culture dish (Iwaki) 
and harvested using 0,25 % Trypsin-EDTA 
(Gibco). 
 
Cytotoxic assay to analyze inhibition of 
HeLa cell proliferation  
Individual wells of 96-well plate (Iwaki) 
were inoculated with 100 µl DMEM medium 
containing 5 x 10
3
 cells. The plate was incubated 
for 24 h to achieve 60-70% confluence. Once the 
cells were confluent, treatment was conducted in 
accordance to pre-calculated concentrations. MTT 
reagent (5 mg/ml, dissolved in medium) was added 
to each well 24 h (single and combination 
treatment) and the plate was incubated for 3 h at 
37˚C. After incubation, SDS 10% v/v in HCl was 
added to the wells followed by gentle shaking to 
dissolve the formazan dye. After an overnight 
incubation, the cell’s absorbance was measured at 
595 nm with a plate reader. Single treatment of 
NGEN and DOX conducted first to determine IC50 
value which was then used to set combination 
dosages. Cell viability and was used as the 
parameter to evaluate combination effectiveness. 
 
Flow cytometry assay to analyze HeLa cell 
cycle distribution 
Flow cytometry enables the identification of 
the cell distribution during the various phase of the 
cell cycle. The Hela cells (5 x 10
5
 cells/well) were 
inoculated in 6-well plate the incubated for 24 h. 
The cells were treated with selected dosage 
according to the cytotoxicity result for 24 h. Two 
eppendorfs were prepared for each treatment, one 
for dead cells (I) and the other for living cells (II). 
To obtain the dead cells, the DMEM growth 
medium was collected into eppendorf I, 
centrifuged at 2000 rpm for 3 minutes, and washed 
twice using PBS. To obtain the living cells, cells 
were harvested using trypsin-EDTA 0.25%, 
collected into eppendorf II, centrifuged at 2000 
rpm for 3 minutes, and washed using PBS. Cells 
inside the two eppendorfs were then combined, 
washed using cold PBS, centrifuged at 2000 rpm 
for 30 second, and the supernatant was disposed. 
Flowcytometry reagent (25µl propidium iodide, 
2.5µl RNase, 0.5µl Triton-X in 500µl PBS) was 
added, followed by incubation at 37˚C for 10 
minutes. The cell suspension were then filtered, 
transferred into a flow cytometer-tube and its cell 
cycle profile was read using Flow cytometer 
FACS-Calibur. Each cell cycle profile was 
analyzed using ModFit LT 3.0. 
 
Double staining apoptosis assay  
Acridine orange (AO) (Sigma)-ethidium 
bromide (EB) (Sigma) dual staining was used to 
identify apoptotic cells. Coverslips (Iwaki) were 
placed in 24-well plates (Iwaki) then 5 x 10
4
 HeLa 
cells were seeded to them, then incubated for 24 h. 
Then, cells were treated with agent as described 
above (cytotoxicity result). Briefly, after 
incubation, medium was removed and cells were 
washed with PBS. Coverslips were removed into 
object glass, stained 10 µl 1x working solution of 
AO-EB and analyzed using fluorescence 
microscope (Zeiss MC 80). Apoptotic cells would 
be seen as reddish-orange fluorescence and viable 
(normal) cells would be seen as green 
fluorescence. 
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Analysis of Bax and Bcl-2 expression using 
Immunocytochemistry method 
Coverslips (Iwaki) were placed in 24-well 
plates (Iwaki) then 5 x 10
4
 HeLa cells were seeded 
to them, then incubated for 24 h. Then, cells were 
treated with agent as described above in the 
cytotoxicity assay, and incubated for 18 h. Culture 
medium were removed and cells were washed in 
PBS. Cells were fixed with cold methanol for 10 
minutes and washed by PBS. Then, cells were 
added with H2O2 blocking solution for 10 minutes 
and removed. Cells were added with prediluted 
blocking serum for 10 minutes, removed, and 
incubated with monoclonal antibody anti-Bax 
(Sigma) or Bcl-2 (Enzo Life Science) for 2 h. 
Then, cells were washed with PBS and incubated 
with biotinylated universal secondary antibody for 
10 minutes, removed, and washed with PBS. Cells 
were incubated with streptavidin-peroxidase 
complex reagent for 10 minutes, removed, and 
washed with PBS. Cells were stained with 
substrate solution DAB for 10 minutes, removed, 
and washed with aquadest. Cells were stained with 
Mayer Haematoxylin for 3 minutes, removed, and 
washed with aquadest. Coverslips were moved into 
object-glass and fixed with ethanol and xylol. 
After that, coverslips were added with mounting 
media and covered by other coverslips. Protein 
expression observed by microscope. Cells with 
positive Bax or Bcl-2 expression appears in 
brown/dark, while cells with negative protein 
expression appears in blue/violet.  
 
RESULTS AND DISCUSSION 
  
Cytotoxic effect of naringenin (NGEN), 
doxorubicin (DOX), and their combination 
on HeLa cells  
In order to assess the potential cell 
proliferation inhibition via cytotoxic effect of 
doxorubicin and naringenin, HeLa cells were 
treated with both samples and cell viabilities were 
determined by MTT assay. The result showed that 
0,5 µM doxorubicin (Fig. 1B) and 100 µM 
naringenin (Fig. 1C) change the HeLa cell 
morphology compared to control (Fig. 1A). 
Doxorubicin and naringenin inhibited the growth 
of HeLa cells in dose-dependent manner (Fig. 1 D 
an F) and IC50 of 24 hours time course were 1 µM 
and 195 µM, respectively. 
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Figure 1.  Cytotoxic effect of DOX and NGEN on cervical cancer HeLa cells. Hela cells (5x103 cells/well) 
were plated in 96-well palte and 24 h after plating, the cells were treated with DOX (0,1-0,8 µM) 
and NGEN (25-1000 µM) for 24 h. (A) cell control. (B) cells with DOX 0,5 µM. (C) cells with 
NGEN 100 µM. The percentage of cell viability were presented on graphic (E) for DOX and (F) 
for NGEN. Data were shown as mean + SD by 3 parallel experiment. The experiment was 
continued by conducting combination of DOX and NGEN on HeLa cells for24 h. (G) cells with 
500 nM DOX-50 µM NGEN. (F) cells with 0,5 µM DOX-100 µM NGEN. The combination gave 
enhanced growth inhibitory effect on HeLa cells, shown in figure (H). Original magnification was 
100x.       cells with morphological change.      
    
The combination dosage of doxorubicin and 
naringenin was set corresponding to the results 
obtained from single treatment. The result showed 
that combination gave enhanced cytotoxic effect 
(Fig. 1 G and F), as shown by further changing of 
cell morphology. The greatest cytotoxic effect was 
given by combination of 0,5 µM doxorubicin-100 
µM naringenin (Fig. 1 F). The cytotoxic result of 
combination application was greater than single 
application showed that combination of 
doxorubicin and naringenin was more effective 
than doxorubicin treatment alone on HeLa cells. 
The morphological changes indicate cell 
death, which in turn corresponds with reduction of 
% viable cells 
IC50 1 µM IC50 195 µM 
Concentration of Doxorubicin (nM) Concentration of Doxorubicin (nM) 
% viable cells 
% viable cells 
Doxorubicin (nm) 
Naringenin (µM) 
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cancer cells proliferation. The antiproliferation 
mechanism of chemotherapy agent may be due to 
cell cycle arrest pathway. Thus, we conducted flow 
cytometry assay to investigate the cell cycle arrest 
effect of doxorubicin and its combination of 
naringenin on HeLa cells. 
 
Effect of doxorubicin, naringenin, and their 
combination on cell cycle arrest induction 
of HeLa cells 
The flow cytometry assay reveals 
distribution of cells in three major phases in cycle 
(G1, S, and G2/M) by determining cellular DNA 
content. The cell control of flow cytometry profile 
depicted normal cell cycle distribution (Fig. 2A) 
wherein the G1 phase takes up the longest time to 
progress. The cells treated with 100 µM naringenin 
showed cell cycle distribution which was not 
noticeably different with the profile of cell control 
(Fig. 2B). Doxorubicin 0,5 µM arrested the cell 
cycle at S phase as much 85,41% (Fig. 2C). The 
combination of 0,5 µM doxorubicin-100 µM 
naringenin showed S arrest (64,17%) with 
increased occurrence of sub-G1 phase (14,35%) 
(Fig. 2D). The combination treatment resulted the 
higher level of cell death compare to the single 
treatment. To verify the indication of cell death by 
apoptosis of flow cytometry result, we also 
conducted apoptosis assay. 
 
Effect of doxorubicin, naringenin, and their 
combination on apoptotic death of HeLa 
cells 
Assessment of apoptotic cells was carried 
out under fluorescence microscope. Apoptotic 
cells would give reddish-orange fluorescence. The 
result showed both 0,5 µM doxorubicin (Fig. 3B) 
and 100 µM naringenin (Fig. 3C)  induced 
apoptosis in HeLa cells and there was not 
apoptotic occurrence in cell control (Fig. 3A). 
Combination of 0,5 µM doxorubicin-100 µM 
naringenin resulted the highest occurrence of 
apoptotic cells and the lowest density of cells (Fig. 
3D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  DOX and NGEN induced cell cycle arrest on cervical cancer HeLa cells. Hela cells 
(5x105 cells/well) were sedded in 6-well plate and 24 h after plating, the cells were 
treated with agents for 24 h. (A) cell control. (B) cells with NGEN 100 µM. (C) cells 
with DOX 0,5 µM. (D) cells with combination of 0,5 µM DOX-100 µM NGEN. The cell 
cycle distribution assay was performed by flow cytometry.  
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Effect of doxorubicin, naringenin, and their 
combination on Bax and Bcl-2 expression of 
HeLa cells 
Apoptosis is a complex cellular process 
involving multiple factors and steps biochemically. 
The balance of two cellular protein families, a pro-
apoptotic protein Bax and an anti-apoptotic protein 
Bcl-2, influences a cell's fate through a intrinsic 
apoptotic pathway. Overexpression of Bax and 
downregulation of Bcl-2 represents an actively 
apoptotic process in the cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  DOX and NGEN induced apoptosis on cervical cancer HeLa cells. Hela cells (5x104 cells/well) 
were plated on coverslips in 24-well plate and 24 h after plating, the cells were treated with 
agents for 24 h. (A) cell control. (B) cells with DOX 0,5 µM. (C) cells with NGEN 100 µM. (D) 
cells with combination of 0,5 µM DOX-100 µM NGEN. Apoptotis assay was conducted by 
acridine orange-ethidium bromide dual staining. Apoptotic cells were reddish-orange 
fluorescence and viable cells were green fluorescence. Original magnification was 400x.              
shows apoptotic cell. 
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The cell control showed no expression of 
Bax (Fig. 4B) and high expression of Bcl-2, 
indicated by intense appearance of brown color in 
cytoplasm (Fig. 4G). These are normal profile of 
HeLa cells because oncoprotein E6 could induce 
Bax degradation on the cells. The cells treated with 
both DOX 0,5 µM and NGEN 100 µM performed 
Bax expression (Fig. 4 C and D) and low Bcl-2 
expression (Fig. 4 H and I). Combination of 0,5 
µM DOX-100 µM NGEN resulted the highest 
Figure 4.  DOX and NGEN increased Bax expression and decreased Bcl-2 expression on Hela cells. Hela 
cells (5x104 cells/well) were seeded on coverslips in 24-well plate and 24 h after plating, the cells 
were treated with agents for 18 h. Pictures A-E are belong to cells given with Bax antibody. 
Pictures are F-J belong to cells given with Bcl-2 antibody. (A and F) cell control without Bax and 
Bcl-2 antibody. (B and G) cell control. (C and H) cells with DOX 0,5 µM. (D and I) cells with 
NGEN 100 µM. (E and J) cells with combination of 0,5 µM DOX-100 µM NGEN. Original 
magnification was 400x. Cells expressed Bax or Bcl-2 showed brown color in cytoplasm. 
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expression of Bax (Fig. 4E) and lowest expression 
of Bcl-2 (Fig. 4J). This is in accordance to the 
apoptosis result that cells treated with combination 
DOX-NGEN had the most apoptotic cells. From 
this result, we conclude that the combination of 
doxorubicin and naringenin increased Bax 
expression and decreased Bcl-2 expression on 
HeLa cells better than its single treatment. 
Doxorubicin and naringenin had the ability 
to inhibit proliferation of HeLa cervical cancer 
cell. Dosage increase corresponds to an increase in 
the antiproliferative effect. When doxorubicin was 
combined with naringenin, the cell proliferation 
inhibition activity increased significantly 
compared with their single treatment. The 
combination showed cytotoxicity synergism. This 
result support our hypothesis that naringenin is a 
promising agent to be combined with doxorubicin 
to improve its chemotherapy effectiveness. 
The antiproliferative mechanism may be 
due to a cell cycle arrest pathway. Our data 
resulted that treatment of doxorubicin arrested 
HeLa cells in S phase while the treatment of 
naringenin did not affect the HeLa cell cycle. S 
phase arrest of doxorubicin is estimated caused by 
the ability of doxorubicin induce Chk1 
phosphorylation (Beckermann et al., 2009). 
Naringenin could bind Cdk2 on its ATP binding 
site so could increase the doxorubicin ability to 
modulate HeLa cell cycle. Cdk2 is produced in late 
G1 phase and participated in transition of G1/S 
phase until S phase progression (Adina et al., 
2008). Inhibition of Cdk2 action by binding with 
substance would induce cell cycle arrest to let the 
cells repair itself, or the cell would undergo 
apoptosis. The combination of doxorubicin and 
naringenin induced S arrest, which meant there is 
dominant influence of doxorubicin. The interesting 
phenomenon was the combination also increase 
the percentage of sub-G1 peak which indicated the 
increase of cell death. 
Our data resulted both doxorubicin and 
naringenin induced apoptosis in HeLa cells via 
mitochondrial pathway. Doxorubicin induces 
apoptosis in cancer cells via activation of caspase 
3, effector of apoptosis pathway, and followed by 
DNA fragmentation (Wang et al., 2004). Reactive 
oxygen species might act as the signal molecules 
for doxorubicin induced apoptosis and the process 
is still functional even in the absence of p53. 
Through ROS pathway, doxorubicin could 
increase Bax expression and decreased Bcl-2 
expression (Tsang et al., 2003). Naringenin 
induced apoptosis in T47D cells, cells with 
mutated p53 (Junedi et al., 2010). Naringenin also 
induced apoptosis via activation of caspase 3 and 
caspase 9 (Jin et al., 2009), increased bax 
expression and decrease Bcl-2 expression (Park et 
al., 2008). In accordance with our result, these 
research suggest that naringenin perform 
synergism effect with doxorubicin to induce 
apoptosis. However, further study about apoptosis 
molecular pathway via activation of caspase 3 is 
needed to determine the claim. 
Doxorubicin usage is restricted by the 
development of resistance to apoptosis. Nuclear 
transcription factor kappaB (NF-κB) has been 
shown both to block apoptosis and to promote cell 
proliferation, and hence has been considered as an 
important target for anticancer drug development 
(Gangadharan et al., 2009). Long term usage of 
doxorubicin also activates cell survival pathway 
PI3K/Akt (Li et al., 2005). Naringenin could 
inhibit NF-κB pathway via preventing IκB  
degradation (Yoshida et al., 2010). Naringenin 
also inhibited cell survival pathway by binding 
ATP on PI3K binding site (Hastuti et al., 2008). 
Through that mechanism, naringenin is expected to 
solve doxorubicin cell resistance problem. This 
research showed that doxorubicin and naringenin 
combination  has good potency as candidate co-
chemotherapy agent for curing cervical cancer. 
Furthermore, the study about anticancer effect of 
the combination doxorubicin and naringenin needs 
to be continued.  
 
CONCLUSION 
 
Naringenin enhances the anti-tumor activity 
of doxorubicin on Hela cervical cancer cells 
through cytotoxic activity, cell cycle modulation, 
and apoptosis induction. Naringenin is a potential 
co-chemotherapy agent for cervical cancer due to 
its synergism with doxorubicin. 
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